Reports Q4 revenue $5.09M, consensus $5.05M. “We are pleased to close out 2024 with record fourth quarter revenue, improved gross margin and growing interest in our unrivalled portfolio of Enterprise Health and Personal Health devices,” said Scott Davis, the company’s CEO. “Looking ahead, our focus will be on aggressively executing two key pillars of our growth strategy: broadening patient access to Ekso Indego Personal and building upon our growing CMS claim pipeline for the device; and further bolstering demand for our legacy EksoNR device. We look forward to updating investors as we progress.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKSO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue